Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Samson who wrote (18318)	1/29/1999 12:17:00 AM
From: VLAD	Respond to of 23519

Andreas, I do not mean to direct my statements as personal attacks.....it just that the tone of your posts are way too gloom and doomish for your own good. Its bad enough that this stock has been heavily under attack by market manipulators etc... I didn't see your finding ANYTHING positive in the cc. I was actually impressed by Astra's ability to get MUSE sales back to preViagra levels 3 months after Viagras release in the three European countries. This demonstrates to me that it is clearly not the product but a lack of effective marketing. The gravy for Vivus is in the United States, Europe and Japan. Now look at how much of these markets are currently being tapped. 1)United States--Never had MUSE effectively marketed. 2)Europe--MUSE to this day only launched in England, Sweden and Switzerland. 3)Japan--ZERO A country such as China IMO is a ? but just may be a gold mine since the Chinese spend over $1B annually in sexual aids. All other countries combined will still take at least one year to get fully launched. There are indeed still some areas that MUSE has has absolutely no exposure such as the Middle East and all countries once compromising the Soviet Union. I have no clue in terms what type of income potential MUSE can see from all the countries in Central and South America once fully launched.

To: Andreas Samson who wrote (18318)	1/29/1999 12:35:00 AM
From: VLAD	Read Replies (1) \| Respond to of 23519

Andreas, Just out of curiosity.....are you in any way impressed by the fact that 3 months after the launch of Viagra, MUSE was able to capture 34% of the ED market in England and 37% of the ED market in Sweden? Did you know that in Sweden the national health care system covers Viagra yet MUSE was still able to rebound to 37% of the ED script count for ED products? Everyone was earlier claiming that they would be happy if MUSE could capture only a mere 5 to 10% of the ED market. Well, it looks to me that conservatively speaking, MUSE if marketed properly may be able to command at least 20 to 25% of the market. I think the most frustrating thing here is that we have a pretty decent product in a rapidly growing market but no marketing arm right here in the land of milk and honey. Another good question for Vivus would have been to ask them exactly what they are currently doing to market MUSE in a cost efficient manner. I never even got a thank you for your input reply from Vivus after we all compiled a list of internet sights which could give MUSE cheap exposure to PCPs and the target group of older folks: www3.techstocks.com